Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices

Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug
                               Delivery Devices

PR Newswire

YORK, Pa., Nov. 11, 2013

YORK, Pa., Nov. 11, 2013 /PRNewswire/ --Unilife Corporation (NASDAQ: UNIS,
ASX: UNS), a U.S. based designer, developer and manufacturer of injectable
drug delivery systems, today announced an agreement with MedImmune, the global
biologics research and development arm of AstraZeneca, to customize and supply
devices from its platform of wearable injectors for use with molecules in
MedImmune's pipeline.

Under this agreement, Unilife will supply MedImmune with customized devices
from its platform of ReadyToGo™ wearable injectors. Several drug candidates
from MedImmune's portfolio may be selected for use with Unilife's wearable
injectors under the agreement.

Mr. Alan Shortall, Chief Executive of Unilife, said, "This is the dawn of a
new era for injectable drug delivery where a very sophisticated new class of
wearable, disposable devices will allow patients to deliver the most advanced
therapies with maximum comfort and convenience. I am delighted that Unilife
is setting the standard in serving biotech customers, such as MedImmune, and
their patients within this category."

"We are pleased that MedImmune selected Unilife's technology after conducting
a thorough evaluation process to identify simple and convenient wearable
injectors that can be used to administer an injectable therapy wherever the
patient is," Mr. Shortall concluded.

Unilife will generate revenue starting in the first quarter of fiscal 2014 on
the basis of the customization and supply of its products to MedImmune.
Additional terms of the contract have not been disclosed.

The wearable injection category is expected to generate device sales in excess
of $3 billion within five to seven years.

Conference Call Information

Unilife is hosting its quarterly earnings conference call at 4:30 p.m. U.S.
EST today, during which the Unilife management team will review its financial
results for the quarter ended September 30, 2013, this contract, other
commercial partnerships and its future outlook. To listen, please go to:

About the ReadyToGo Wearable Injectors

The Unilife portfolio of ReadyToGo wearable injectors is a game-changing
platform that addresses the unmet needs of biotech customers in delivering
high-dose volume therapies wherever the patients are. The ReadyToGo wearable
injectors are supplied to the patient prefilled with the drug and
ready-for-injection with no extra steps or parts required. Only three simple
steps are required to inject the dose: peel, stick, click, with an on-body
safety interlock, a Flexwear™ comfort catheter and an electronic user
interface among an array of features that maximize patient comfort and
awareness during all stages of use. The devices are designed to minimize
disruption to a patient's normal daily lifestyle during the period of dose

The ReadyToGo wearable injectors are designed for integration with standard
filling processes, utilize standard materials in the primary drug container
and require no terminal sterilization. A fully programmable delivery regimen
allows the bolus, basal or variable rate of dose delivery to be customized to
specific customer, therapy and patient requirements. The electronics in the
device can be easily detached and disposed for markets that require special
electronics disposal procedures. A video of Unilife's platform of wearable
injectors can be viewed on the Unilife website at http://bit.ly/19MYWTA.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and
commercial supplier of injectable drug delivery systems. Unilife's broad
portfolio includes prefilled syringes with automatic needle retraction, drug
reconstitution delivery systems, auto-injectors, wearable injectors, ocular
delivery systems and novel devices. Each of these innovative, differentiated
platforms can be customized by Unilife to address specific customer, drug and
patient requirements. Unilife's global headquarters and state-of-the-art
manufacturing facilities are located in York, PA. For more information, please
visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or
Android device.

Forward-Looking Statements

Thispress release contains forward-looking statements. All statements that
address operating performance, events or developments that we expect or
anticipate will occur in the future are forward-looking statements.These
forward-looking statements are based on management's beliefs and assumptions
and on information currently available to our management. Our management
believes that these forward-looking statements are reasonable as and when
made. However, you should not place undue reliance on any such forward-looking
statements because such statements speak only as of the date when made. We do
not undertake any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise, except as required by law. In addition, forward-looking statements
are subject to certain risks and uncertainties that could cause actual
results, events and developments to differ materially from our historical
experience and our present expectations or projections. These risks and
uncertainties include, but are not limited to, those described in "Item1A.
Risk Factors" and elsewhere inourAnnual Report on Form 10-Kand those
described from time to time in other reports which we file with the Securities
and Exchange Commission.

General: UNIS-G

Investor and PR Contacts (US):  Analyst Enquiries    Investor Contacts
Todd Fromer / Garth Russell   Lynn Pieper    Jeff Carter

KCSA Strategic Communications     Westwicke Partners   Unilife Corporation
P: + 1 212-682-6300               P: + 1 415-202-5678 P: + 61 2 8346 6500

SOURCE Unilife Corporation

Website: http://www.unilife.com
Press spacebar to pause and continue. Press esc to stop.